Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

OCOnyee ChanMWMichael J. WalkerDNDeedra Nicolet

Discussion

Loading...

Member takes

Overview

Observational analysis revealed overall survival disparities for IDH1/2-mutated acute myeloid leukemia patients receiving venetoclax or hypomethylating agents, indicating therapy optimization needs.

Key Points

  • IDH1/2-mutated acute myeloid leukemia patients treated with venetoclax showed better outcomes.
  • Among 939 patients, those receiving venetoclax achieved higher overall survival rates than with hypomethylating agents.
  • Retrospective analysis compared treatment responses in multiple cancer centers and community practices.
  • Identification of TP53 mutations suggests potential targets for therapy improvement in IDH1/2-mutated cases.

Cite This Study

Chan et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e452https://doi.org/10.1182/blood-2025-1626
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  2. 2Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025
  3. 3IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies2025
  4. 4A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  5. 5Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025